|
Univariate analysis
|
|
Gender (Male vs. female)
|
0.290 (0.040–2.124)
|
0.223
|
0.345 (0.047–2.517)
|
0.294
|
|
Age (y) (< 60 vs. ≥60)
|
0.786 (0.401–1.507)
|
0.469
|
0755 (0.401–1.423)
|
0.385
|
|
Alcohol (Light vs. Heavy)
|
1.711 (0.873–3.354)
|
0.118
|
1.825 (0.940–3.543)
|
0.075
|
|
Smoking (Light vs. Heavy)
|
1.261 (0.664–2.395)
|
0.479
|
1.239 (0.664–2.311)
|
0.501
|
|
Stage (I/II vs. III/IV)
|
1.421 (0.744–2.714)
|
0.288
|
1.559 (0.830–2.927)
|
0.167
|
|
Differentiation (WD vs. MD/PD)
|
1.425 (0.641–3.170)
|
0.385
|
1.418 (0.667–3.018)
|
0.364
|
|
Location (upper/middle vs. lower)
|
1.139 (0.560–2.316)
|
0.720
|
1.305 (0.658–2.591)
|
0.446
|
|
Adjuvant therapy
|
1.437 (0.698–2.960)
|
0.325
|
1.814 (0.916–3.593)
|
0.088
|
|
Resection margin (R0 vs. R1)
|
1.050 (0.370–2.976)
|
0.927
|
1.286 (0.454–3.638)
|
0.636
|
|
Vascular invasion
|
1.992 (1.009–3.934)
|
0.047
|
1.932 (0.992–3.765)
|
0.053
|
|
Lymphatic invasion
|
1.856 (0.944–3.648)
|
0.073
|
1.905 (0.989–3.671)
|
0.054
|
|
Perineural invasion
|
1.951 (0.934–4.073)
|
0.075
|
2.083 (0.998–4.345)
|
0.051
|
|
Dysplasia
|
0.574 (0.296–1.115)
|
0.101
|
0.478 (0.716–3.064)
|
0.031
|
|
PD-L1 (negative vs. positive)
|
0.084 (0.256–1.090)
|
0.078
|
0.458 (0.222–0.944)
|
0.034
|
|
MSI/dMMR
|
1.667 (0.780–3.564)
|
0.187
|
1.804 (0.879–3.704)
|
0.108
|
|
PIK3CA mutation
|
1.876 (0.777–4.530)
|
0.162
|
1.818 (0.756–4.373)
|
0.182
|
|
Multivariate analysis
|
|
Vascular invasion
|
1.818 (0.824–4.009)
|
0.139
|
1.622 (0.726–3.623)
|
0.239
|
|
Lymphatic invasion
|
1.557 (0.707–3.429)
|
0.271
|
1.725 (0.747–3.983)
|
0.202
|
|
Perineural invasion
|
1.435(0.646–3.188)
|
0.376
|
1.069(0.449–2.544)
|
0.880
|
|
PD-L1 (negative vs. positive)
|
0.416 (0.196–0.885)
|
0.023
|
0.379 (0.174–0.824)
|
0.014
|
|
Alcohol (Light vs. Heavy)
|
–
|
–
|
1.792(0.868–3.701)
|
0.115
|
|
Adjuvant therapy
|
–
|
–
|
2.009(0.896–4.504)
|
0.090
|
|
Dysplasia
|
–
|
–
|
0.701(0.341–1.444)
|
0.336
|
